A detailed history of Pro Share Advisors LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Pro Share Advisors LLC holds 12,388 shares of ADCT stock, worth $49,056. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,388
Previous 14,855 16.61%
Holding current value
$49,056
Previous $39,000 25.64%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

SELL
$2.64 - $4.02 $6,512 - $9,917
-2,467 Reduced 16.61%
12,388 $49,000
Q2 2025

Aug 07, 2025

SELL
$1.1 - $3.67 $3,025 - $10,092
-2,750 Reduced 15.62%
14,855 $39,000
Q1 2025

May 08, 2025

SELL
$1.39 - $2.02 $7,361 - $10,697
-5,296 Reduced 23.13%
17,605 $24,000
Q4 2024

Feb 13, 2025

BUY
$1.89 - $3.48 $14,241 - $26,221
7,535 Added 49.04%
22,901 $45,000
Q3 2024

Nov 13, 2024

BUY
$2.59 - $4.01 $39,797 - $61,617
15,366 New
15,366 $48,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $307M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.